GENERAL, O. Reg. 201/96

Section 18

Cite as GENERAL, O. Reg. 201/96, s. 18 · current to November 11, 2026 · consolidated from July 1, 2026 · read from e-Laws on November 16, 2026

The text

(1) Revoked: O. Reg. 134/18, s. 1 (1). (2) If an eligible person will be leaving Ontario for a period of at least 100 consecutive days within six months after the day a listed drug product is supplied for the person, the executive officer is only required to pay under the Act for the quantity of the product supplied for the person at one time that is sufficient for a 100-day course of treatment. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (2). (3) The executive officer is only required to pay under the Act for the quantity of a listed drug product supplied for an eligible person, other than a person mentioned in subsection (2), at one time that is sufficient for a 30-day course of treatment if the product supplied is a product other than insulin and if the product supplied has not been supplied for the person within the previous 12-month period. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (3); O. Reg. 134/18, s. 1 (2). (4) Despite subsection (3), the executive officer is required to pay for the quantity of a listed drug product described in that subsection that is sufficient for a 100-day course of treatment if, in the opinion of the person dispensing the product, the person will not be able to obtain a further supply of the product at the end of a 30-day course of treatment. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (4). (5) The executive officer is only required to pay under the Act for the quantity of a listed drug product supplied for an eligible person, other than a person mentioned in subsection (2), at one time that is sufficient for a 100-day course of treatment if the listed drug product supplied is a product other than one mentioned in subsection (3). O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (5); O. Reg. 134/18, s. 1 (3). (6) The following rule applies for the purposes of subsections (2), (4) and (5): 1. If a listed drug product is supplied for a person who is part of the eligible class of persons designated under section 3 and if, by supplying a 100-day course of treatment of the product, the last day of the course of treatment would be more than 30 days after the end of the period for which the person is eligible, the executive officer is only required under the Act to pay for the quantity of the listed drug product sufficient for a course of treatment that ends 30 days after the end of the period for which the person is eligible. O. Reg. 301/02, s. 1; O. Reg. 459/06, s. 14 (6). (7) It is a condition for payment of a dispensing fee that the dispenser supply at one time to an eligible person the lesser of, (a) the maximum quantity of a listed drug product for which the executive officer is required to pay under subsections (2) to (6); or (b) the maximum quantity of the listed drug product that the dispenser is authorized to supply at one time. O. Reg. 264/08, s. 1 (1); O. Reg. 284/15, s. 3 (1); O. Reg. 134/18, s. 1 (4). (8) The condition for payment of a dispensing fee set out in subsection (7) does not apply if, (a) the listed drug product is a product or belongs to a class of drug product that is specified by the executive officer and published on the Ministry website and the dispenser has determined that the quantity supplied should be less than the amount required under subsection (7) because, in the dispenser’s professional opinion, (i) the safety of the eligible person is a concern, or (ii) there is a risk of abuse or diversion if the drug product is supplied to the eligible person; (b) the eligible person is a resident of a residential facility, other than a long-term care home under the Fixing Long-Term Care Act, 2021, that is funded by the Government of Ontario and is designated by the executive officer in a designation published on the Ministry website; or (c) the dispenser has determined that the quantity supplied should be less than the amount required under subsection (7) because, (i) in the dispenser’s professional opinion, the eligible person is incapable of managing his or her medication as a result of physical, cognitive or sensory impairment, and (ii) the eligible person or the person presenting the prescription agrees that the quantity supplied should be less than the amount required under subsection (7). O. Reg. 264/08, s. 1 (1, 2); O. Reg. 284/15, s. 3 (2); O. Reg. 431/19, s. 3 (1); O. Reg. 309/22, s. 2 (1). (8.1) Where the dispenser has made a determination under clause (8) (a), (a) the dispenser shall make a written record of the reasons for his or her opinion; (b) the dispenser shall notify the prescriber in writing about the determination and retain a copy of the notification; and (c) the dispenser shall provide copies of the written record described in clause (a) and the written notification described in clause (b) to the executive officer on request. O. Reg. 284/15, s. 3 (3). (9) Where the dispenser has made a determination under clause (8) (c), (a) the dispenser shall make a written record of the reasons for his or her opinion under subclause (8) (c) (i); (b) the dispenser shall obtain in writing the agreement required under subclause (8) (c) (ii) of the eligible person or of the person presenting the prescription; (c) the dispenser shall notify the prescriber in writing about the determination and retain a copy of the notification; and (d) the dispenser shall provide copies of the written record, agreement and notification described in clauses (a), (b) and (c) to the executive officer on request. O. Reg. 284/15, s. 3 (4). (10) The executive officer shall not pay more than two dispensing fees for the supply of a listed drug product in a 28-day period even if the prescription specifies intervals such that the listed drug product is to be dispensed in more than two intervals in the 28-day period, unless, (a) the listed drug product is dispensed in the circumstances described in clause (8) (a) or (b); or (b) the listed drug product is a product or belongs to a class of drug product that is specified by the executive officer and published on the Ministry website. O. Reg. 284/15, s. 3 (4); O. Reg. 93/16, s. 1. (11) Pursuant to subsection 1.1 (9) of the Act, it is provided that the executive officer has the power, (a) to specify a listed drug product or class of listed drug product for the purposes of clauses (8) (a) and (10) (b); and (b) to designate a residential facility for the purposes of clauses (8) (b) and (11.1) (a). O. Reg. 284/15, s. 3 (4); O. Reg. 431/19, s. 3 (2). (11.1) Despite subsection (10), where the listed drug product is a product or belongs to a class of drug product that has been specified by the executive officer and published on the Ministry’s website, the executive officer shall not pay more than five dispensing fees in a year for the supply of the listed drug product, even if the intervals specified in the prescription provide for the listed drug product to be dispensed more than five times in the year, unless the listed drug product, (a) is supplied to an eligible person who is a resident of a residential facility, other than a long-term care home under the Fixing Long-Term Care Act, 2021, that is funded by the Government of Ontario and is designated by the executive officer in a designation published on the Ministry website; (b) Revoked: O. Reg. 134/18, s. 1 (5). (c) is supplied to an eligible person who is on a complex medication regime that has been specified by the executive officer and published on the Ministry’s website and who requires more frequent dispensing of the listed drug product to assist with the proper administration of the medication regime; (d) is supplied in accordance with clause 18 (8) (c) and subsection 18 (9) of this Regulation; or (e) is an extemporaneous preparation. O. Reg. 284/15, s. 3 (4); O. Reg. 134/18, s. 1 (5); O. Reg. 431/19, s. 3 (3); O. Reg. 309/22, s. 2 (2). (11.2) For the purposes of subsection (11.1), “year” is a period of 365 days, with the first year commencing on the day the first claim for payment for the relevant listed drug product is submitted by the dispenser to the executive officer following the coming into force of subsection (11.1), and all subsequent years commencing on the day the first claim for payment for the relevant listed drug product is submitted by the dispenser to the executive officer following the end of the previous year. O. Reg. 284/15, s. 3 (4). (11.3) Pursuant to subsection 1.1 (9) of the Act, it is provided that the executive officer has the power, (a) to specify a listed drug product or class of listed drug product for the purposes of subsection (11.1); and (b) to specify a complex medication regime for the purposes of clause (11.1) (c). O. Reg. 284/15, s. 3 (4). (12) If the executive officer specifies a listed drug product or class of listed drug product under clause (11) (a) or designates a residential facility under clause (11) (b), he or she shall publish the specification or designation on the Ministry website. O. Reg. 264/08, s. 1 (1).
Read the GENERAL on e-Laws ↗

Made under Ontario Drug Benefit Act, R.S.O. 1990, c. O.10.